drugset / Trial / NCT03933982
A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, open label clinical study of pyrotinib plus vinorelbine as the therapy of brain metastases from HER2-positive metastatic breast cancer.
Timeline
- Start
- 2018-12-22
- Primary completion
- 2021-12-22
- Completion
- 2022-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 320 mg | Oral |
| Subject | Vinorelbine | Small molecule | 60 mg/m2 | Oral |